Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/Oncologyquartz Rituximab IV Coverage & Prior Auth | OpenPa…
    Ask Trek AI about this page
    CurrentquartzPolicy N/A

    Rituximab Intravenous Products Clinical Resource

    Customize your policy alerts

    Sign up for all quartz policy alerts

    Know when quartz releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs Quartz coverage, clinical guidance, dosing, and prior authorization requirements for rituximab intravenous products (brand and biosimilars) across approved indications for affected members and providers.

    Policy Summary
    Payerquartz
    PolicyRituximab Intravenous Products Clinical Resource
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateFeb 26, 2025
    Last ReviewFeb 26, 2025
    Next Review DateFeb 26, 2025
    Key ActionVerify prior therapies and prescriber specialty and obtain medical necessity review for brand Rituxan; biosimilars do not require prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    6indications
    No PAbiosimilars PA
    PA requiredRituxan PA
    Dose examples listeddose examples
    >=6 months

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    min intervals

    Coverage Criteria and Indication-Specific Requirements

    Covered indications with criteria

    Covered when ALL of the following are met (per indication):

    ANCA-associated vasculitis - induction: Patient has an ANCA-associated vasculitis AND rituximab is administered in combination with glucocorticoids AND prescribed by or in consultation with a rheumatologist, nephrologist, or immunologist.
    ANCA-associated vasculitis - follow-up: Patient received induction treatment and achieved disease control per prescriber AND if patient previously received a course, at least 16 weeks elapsed between courses.
    B-cell lymphomas: Diagnosis is a B-cell lymphoma (examples listed in policy) AND dosing conforms to specified regimens (e.g., up to 375 mg/m2 per dose with doses separated by ≥7 days or 375 mg/m2 on two days of each cycle).
    Chronic lymphocytic leukemia/small lymphocytic lymphoma: Diagnosis of CLL/SLL AND dosing up to 500 mg/m2 IV on 1 day of each cycle.
    Pemphigus vulgaris - initial: Use for 1 month in combination with a corticosteroid unless contraindicated AND prescribed by or in consultation with a dermatologist.
    Pemphigus vulgaris - relapse/maintenance: Subsequent infusions no sooner than 16 weeks after prior infusion AND dermatologist monitoring/consultation.
    Rheumatoid arthritis: Patient has tried one conventional synthetic DMARD for ≥3 months AND rituximab will not be used concurrently with another biologic or targeted synthetic DMARD AND prescribed by or in consultation with a rheumatologist; maintenance courses separated by ≥16 weeks.
    Immune thrombocytopenia (ITP): Patient tried one other therapy (e.g., IVIG, anti-D, corticosteroids, splenectomy) AND if prior rituximab course given, at least 6 months elapsed between courses and patient responded to prior therapy as determined by prescriber.
    Immunotherapy-related toxicities: Patient symptomatic despite trial of at least one systemic corticosteroid AND prescribed by or in consultation with an oncologist, neurologist, rheumatologist, or dermatologist.
    Multiple sclerosis: Inadequate response or intolerance to at least two other disease-modifying agents for MS AND rituximab will not be used concurrently with another MS DMT AND at least 6 months elapse between treatment courses when repeating therapy.

    General Dosing Options

    Covered when ALL of the following dosing options are met for listed hematology/oncology indications:

    Oncology dosing options: Either 500 mg/m2 IV x2 doses separated by ≥14 days OR 375 mg/m2 IV x4 doses separated by ≥7 days.

    General dosing patterns (policy dosing section).

    Multiple Sclerosis — Initial or Repeat Courses

    Covered for Multiple Sclerosis when ALL of the following are met:

    MS eligibility: Patient had inadequate response or was unable to tolerate at least TWO other disease-modifying agents for MS; medication will not be used concurrently with another MS disease-modifying agent; at least 6 months will elapse between treatment courses when repeating therapy.>=6 months between courses

    Dosing: up to 2,000 mg total administered as one or two IV infusions over 1 month.

    Neuromyelitis Optica Spectrum Disorder — Dosing

    Covered for Neuromyelitis Optica Spectrum Disorder when dosing matches one of the following:

    NMOSD dosing options: Up to 375 mg/m2 IV with doses separated by ≥7 days OR up to two 1,000 mg IV doses separated by ≥2 weeks.

    (policy dosing section).

    Primary Central Nervous System Lymphoma — Dosing

    Covered for Primary Central Nervous System Lymphoma when dosing is:

    PCNSL dosing: Use up to 375 mg/m2 IV with doses separated by at least 7 days.

    (policy dosing section).

    Systemic Lupus Erythematosus — Use Conditions

    Covered for SLE when ALL of the following are met:

    SLE eligibility: Patient has tried at least ONE standard immunomodulating or immunosuppressant agent; AND for a patient who already received a rituximab course, use for 1 month is appropriate if at least 6 months will elapse between treatment courses (i.e., ≥6 months between first doses of consecutive courses).>=6 months between courses for repeats

    (policy guidance).

    Waldenstrom's Macroglobulinemia/LPL — Dosing

    Covered for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma when dosing is:

    Waldenstrom dosing: Use up to 375 mg/m2 IV with doses separated by at least 7 days.

    (policy dosing section).

    Requests for the brand product Rituxan require evaluation of medical necessity and are not covered without review. Rituxan Hycela (rituximab/hyaluronidase subcutaneous) has only been evaluated following at least one full IV rituximab dose for certain lymphomas and CLL, has not been evaluated for non-malignant conditions, and is not interchangeable with other rituximab products.

    Use of rituximab is not recommended in clinical circumstances where supporting data are lacking; such indications should not be approved when evidence does not support benefit.

    The brand product Rituxan requires a prior medical necessity review and is not covered without approval. Biosimilar rituximab products have demonstrated biosimilarity but brand Rituxan still requires evaluation of medical necessity prior to use.

    Indications for rituximab that lack adequate supporting clinical data are considered not recommended for approval and are treated as not medically necessary in the absence of evidence of benefit.

    Provider Requirements, Prior Authorization, and Documentation

    Prior Authorization

    Prior authorization: biosimilars vs. brand Rituxan

    Rituximab biosimilar products (e.g., Riabni, Ruxience, Truxima) do not require prior authorization. In contrast, requests for BRAND Rituxan require a medical necessity review and are not covered without approval; Medicare Advantage requests may also be subject to NCDs/LCDs.

    Prior Authorization

    Prior authorization: verify prerequisite therapies and intervals

    Prior authorization reviews must verify that required prior therapies and minimum intervals are met for the requested indication (examples below include MS and SLE).

    • Multiple sclerosis: documentation of inadequate response or intolerance to at least TWO other disease‑modifying agents and that rituximab will not be used concurrently with another MS DMT; confirm at least 6 months between courses when repeating therapy.
    • Systemic lupus erythematosus: documentation of trial of at least ONE standard immunomodulating or immunosuppressant agent; for repeat courses, confirm 6 months or greater between course start dates.

    Dosing Regimens and Administration Schedules

    IndicationRegimen / Dosing (IV)Coverage status
    Non-Hodgkin lymphoma and other B-cell lymphomas (e.g., follicular, DLBCL, mantle cell, marginal zone, Burkitt, primary mediastinal, primary cutaneous, post-transplant lymphoproliferative disorders, pediatric aggressive mature B-cell)
    Rituximab combined with first-line chemotherapy (e.g., CHOP or other anthracycline-based regimens) or as single-agent maintenance after response. Dosing examples: 375 mg/m2 IV per dose with doses separated by ≥7 days, OR 375 mg/m2 IV on two days of each cycle.
    IndicationRegimen / Dosing (IV)Coverage status
    Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma (SLL) in combination with fludarabine and cyclophosphamide (FC)
    Use up to 500 mg/m2 administered as an intravenous infusion on 1 day of each cycle.
    Indication or ContextRegimen / Dosing (IV)Coverage status
    Oncology common dosing (various hematologic malignancies)
    375 mg/m2 IV per dose with doses separated by ≥7 days; alternative oncology option: 500 mg/m2 IV x2 doses separated by ≥14 days.
    Neuromyelitis optica spectrum disorder (NMOSD)
    Up to two 1000 mg IV doses separated by ≥2 weeks.
    Multiple sclerosis (MS) — per-course total dosing
    Up to 2,000 mg total administered as one or two IV infusions over 1 month.

    Line of Therapy and Positioning

    first-line

    First-line positioning: Rituximab is included across first-line, induction, maintenance, and subsequent therapy regimens per disease-specific guidelines and NCCN recommendations.

    not_specified

    Line of therapy not specified: Dosing options include up to 375 mg/m2 IV with doses separated by ≥7 days; alternatives include 500 mg/m2 x2 separated by ≥14 days or 375 mg/m2 x4 separated by ≥7 days.

    Definitions and Biomarker/Other Requirements

    Biosimilar
    Approved biosimilarsRiabni, Ruxience, and Truxima are approved as biosimilars to Rituxan with no clinically meaningful differences in safety or effectiveness.
    Interchangeability statusThe biosimilars have demonstrated biosimilarity but not interchangeability at this time.
    Shared product attributesBiosimilars share mechanism of action, route of administration, dosage form, and strength with Rituxan; minor differences in inactive components are allowed.
    Prior authorization implicationRituxan brand requires medical necessity review prior to use; biosimilars do not require designation as interchangeable in the document.
    Rituxan Hycela
    DefinitionRituxan Hycela is rituximab/hyaluronidase subcutaneous injection (Genentech) intended for use after at least one full IV rituximab dose for certain lymphomas and CLL.

    Clinical Background

    Rituximab products are CD20-directed cytolytic antibodies that deplete CD20-expressing B cells and are used across a range of hematologic malignancies and immune-mediated disorders. Approved IV indications include multiple B‑cell malignancies (for example, various non‑Hodgkin lymphomas and chronic lymphocytic leukemia) as well as selected autoimmune diseases such as rheumatoid arthritis and pemphigus vulgaris; rituximab subcutaneous formulation (Rituxan Hycela) is indicated only after at least one full IV dose for certain lymphomas/CLL and has not been evaluated for non‑malignant conditions.

    Policy Revision History

    2025-02-26policy_reviewLatest

    Last review and policy effective date — clinical resource for rituximab IV products updated and confirmed current.

    Policy Summary
    Payerquartz
    PolicyRituximab Intravenous Products Clinical Resource
    Policy CodePolicy N/A
    Change TypeAnnual review — no material changes
    Effective DateFeb 26, 2025
    Last ReviewFeb 26, 2025
    Next Review DateFeb 26, 2025
    Key ActionVerify prior therapies and prescriber specialty and obtain medical necessity review for brand Rituxan; biosimilars do not require prior authorization.
    SourceLink
    On This Page
    Coverage Criteria and Indication-Specific RequirementsProvider Requirements, Prior Authorization, and DocumentationDosing Regimens and Administration SchedulesLine of Therapy and PositioningDefinitions and Biomarker/Other RequirementsClinical BackgroundPolicy Revision History
    Step Therapy

    Step therapy prerequisites (general)

    For some indications the policy requires documented prior trials before initiating rituximab (step therapy).

    • Rheumatoid arthritis: trial of ONE conventional synthetic DMARD for ≥3 months prior to rituximab.
    • Immune thrombocytopenia (ITP): trial of one other therapy such as IVIG, anti‑D immunoglobulin, corticosteroids, or splenectomy prior to rituximab.
    • Multiple sclerosis: inadequate response or intolerance to at least TWO other DMTs prior to rituximab.
    Step Therapy

    Step therapy specifics for MS and SLE

    Certain indications specify exact step therapy or failure/intolerance requirements and minimum timing between courses.

    • MS: failure or intolerance to ≥2 other disease‑modifying therapies and at least 6 months between courses.
    • SLE: trial of ≥1 standard immunomodulating or immunosuppressant agent; if repeating a course, ensure ≥6 months between course start dates.
    Documentation Required

    Required prescriber specialty and consultations

    Prescriber specialty must be documented for certain indications and prescriber consultation/monitoring is required for others.

    • Rheumatoid arthritis: prescribed by or in consultation with a rheumatologist.
    • Pemphigus vulgaris: prescribed by or in consultation with a dermatologist; dermatologist should monitor relapse/maintenance.
    • ANCA‑associated vasculitis: prescribed by or in consultation with a rheumatologist, nephrologist, or immunologist.
    • Immune‑related toxicities: prescribed by or in consultation with an oncologist, neurologist, rheumatologist, or dermatologist.
    Documentation Required

    Prior therapy, response, and timing documentation required

    Authorization requests must include documentation of prior therapy use, outcomes, and dates to confirm required timing between courses where specified.

    • Document prior use and intolerance or inadequate response to required therapies (e.g., ≥2 DMTs for MS; ≥1 immunomodulating agent for SLE).
    • When repeating a rituximab course, provide dates of prior rituximab doses to confirm minimum intervals (e.g., ≥6 months between course start dates for MS and SLE; ≥16 weeks for some maintenance uses).
    • For ITP, document prior response to the previous rituximab course and evidence of relapse if proposing retreatment after ≥6 months.
    Denial Risk

    Brand Rituxan requires medical necessity review

    Requests for brand Rituxan will be evaluated for medical necessity prior to approval; brand Rituxan is not covered without this review and may be denied if criteria are not met.

    Denial Risk

    Not recommended uses — insufficient evidence

    Use of rituximab is not recommended where clinical data do not support its use; such indications are not recommended for approval.

    • Conditions explicitly listed under 'Conditions Not Recommended for Approval' should not be approved because evidence does not support rituximab use.
    Evaluation statusRituxan Hycela has not been evaluated for non-malignant conditions.
    InterchangeabilityRituxan Hycela is NOT interchangeable with other rituximab products.
    Course
    DefinitionA treatment course denotes the period required to receive the described dosing regimen for the indication-specific schedule.
    Multiple Sclerosis exampleMS: up to 2,000 mg total administered as one or two IV infusions over 1 month (one course).
    Systemic Lupus Erythematosus exampleSLE: one month is considered adequate duration to receive one course; repeat courses require ≥6 months between first doses of successive courses.
    CD20
    Biomarker requirementCD20 positivity is required for use in CD20-positive disease (e.g., certain acute lymphoblastic leukemias and B‑cell lymphomas).
    RelevanceCD20 is referenced for disease-specific eligibility where applicable (oncology indications).
    Dosing linked to CD20 indicationsDosing for CD20-positive ALL: up to 375 mg/m2 IV with doses separated by ≥7 days.